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Abstract 
Objectives: Altered awareness of motor symptoms is reported in people with Parkinson’s disease 
and Dementia with Lewy Bodies, and may adversely affect quality of life and medication 
concordance. How symptom awareness is influenced by motor and cognitive disease severity, age 
and medication use is not fully understood. We carried out a systematic review of the literature on 
motor symptom awareness in Parkinson’s disease and Dementia with Lewy Bodies. 
Methods: Pubmed and Wed of Science were searched for relevant articles published in or prior to 
March 2019. Data regarding participant demographics, diagnosis, cognitive status, method of 
assessing awareness and study findings were extracted from relevant publications.  
Results: 16 relevant publications were identified. Motor symptom awareness appears to decline 
over the course of Parkinson’s disease. Imaging studies implicate the prefrontal cortex, with 
different mechanisms involved in hypokinesia and dyskinesia awareness. The hypothesis that people 
with right hemisphere based disease would have more severely reduced awareness is only weakly 
supported. Most studies focused on cognitively intact individuals, and on awareness of dyskinesia 
rather than hypokinesia.  
Conclusions: Whilst reduced awareness of dyskinesia and to a lesser extent hypokinesia is common, 
there is a lack of longitudinal data on how awareness changes over time, and how it interacts with 
global cognitive changes.  Motor symptom awareness in Dementia with Lewy Bodies is 
understudied. Future studies of symptom awareness should include robust assessment of overall 
cognitive functioning, and use a longitudinal design to elucidate how awareness changes over time.   
 
Keywords: 
Symptom awareness  Parkinson’s disease 
Insight    Parkinson’s disease dementia 




Reduced awareness of motor symptoms is a common phenomenon in Parkinson’s disease. 
Impaired monitoring of planned versus executed movements may contribute to reduced dyskinesia 
awareness in Parkinson’s disease.  
Dopaminergic medications impact on motor symptom awareness in Parkinson’s disease.  
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The prefrontal cortex is involved in motor symptom awareness in Parkinson’s disease, with differing 
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1. Introduction 
  
Parkinson’s disease (PD) is a common neurodegenerative disorder, which encompasses a range of 
motor and non-motor symptoms1. PD is associated with multiple neuroanatomical and 
neurotransmitter abnormalities which can impact on awareness of symptoms across a range of 
modalities2–5. Impaired symptom awareness, also referred to as anosognosia or loss of insight, can 
be conceptualised as the inability to accurately gauge one’s level of functioning or degree of 
symptomatology6,7. The term ‘metacognition’ is used in reference to the process of ‘thinking about 
thinking’ – that is, to be aware of one’s own level of functioning in different cognitive and physical 
domains8,9. Awareness of one’s memory functioning is termed ‘meta-memory’. Loss of insight may 
therefore also be referred to as impaired metacognition. Individuals may be unaware of how their 
motor symptoms affect personal safety and how they assess risk (for example, whether or not they 
can safely drive), or the degree of side effects such as dyskinesias10–13. Altered symptom awareness 
affects healthcare seeking behaviour and medication concordance12,14.  Untreated motor and non-
motor symptoms can have a negative impact upon the quality of life of the individual and contribute 
to carer strain15–17.   
 
Improving our understanding of insight in PD is particularly relevant given the projected future 
increases in the number of people affected by PD worldwide18.  Dementia is a frequent complication 
of PD, with over 70% of people diagnosed with PD developing  Parkinson’s Disease Dementia (PDD) 
over time19. Clinically and pathologically, PDD is closely related to Dementia with Lewy Bodies (DLB), 
with the two conditions being distinguished by the sequence and severity in which motor and 
cognitive symptoms occur20,21. Clinically significant altered awareness is a feature of multiple 
different forms of dementia, including PDD and DLB2,6. The impact of DLB on symptom awareness is 
a particularly understudied area. Loss of symptom awareness is therefore an important topic, and 
one which has received increasing research attention in recent years.  
 
Work with healthy control subjects and people with Alzheimer’s disease (AD) implicates the 
cingulate cortex, insula and prefrontal cortex (PFC) as critical areas for symptom awareness22–24. Loss 
of awareness of memory, social and behavioural functioning in AD has been strongly associated with 
atrophy of the medial temporal lobe (MTL)25, but it is unclear if different aspects of awareness (for 
example awareness of motor symptoms vs awareness of memory impairment) are supported by 
different brain networks. The MTL and medial PFC are strongly interconnected, as are the medial 
PFC and the anterior cingulate cortex (ACC). Additionally, a network spanning the posterior parietal 
cortex, supplementary motor area and premotor cortex is proposed to support the conscious 
experience of voluntary motor actions26. A particular role for the right hemisphere (and by extension 
the right basal ganglia) has been inferred from the experience of anosognosia in stroke patients 
being particularly right hemisphere related27.  
 
Regional brain atrophy accumulates over time in PD, affecting the frontal lobes, medial temporal 
lobes, and hippocampus28. Parallels are seen between the severity and distribution of atrophy and 
cognitive performance29. Atrophy is most widespread and severe in PDD, although relative 
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preservation of the MTL is seen in comparison with AD28. The neural regions and networks sub-
serving conscious recognition of symptoms are therefore at risk in PD. Additional potential for 
malfunctioning symptom awareness comes from changes to neurotransmitter systems in PD30,31.  
 
This systematic review discusses the findings from studies of awareness of motor symptoms in PD 
and DLB, including the impact of dopaminergic medication and global cognitive status. We provide a 
critical analysis of current knowledge and propose future research directions.  
 
2. Methods 
A systemic review was undertaken of the literature investigating altered insight in PD and DLB, 
across motor symptoms, neuropsychiatric and cognitive symptoms. The findings for awareness of 
motor symptoms are reported in the current publication. In order to capture the extent of the 
literature a range of search terms were used. Either 'Parkinson's' or 'Lewy body' were used as a term 
to denote the disease of interest, combined with either 'insight', 'anosognosia' or 'metacognition' to 
denote the cognitive area of interest. The term ‘awareness’ was not used as a search term due to 
the high frequency of off-topic usage in the English language. Searches were conducted between 
January and March 2019, limited to papers published in English and dealing with humans. Pubmed 
and Wed of Science searches were conducted. Duplicates were excluded, followed by screening by 
title, then abstract. Relevant publications detailing investigations of insight in PD or DLB were then 
selected after a full review of the text. Additional relevant publications were identified from these 
selected publications. Screening of publications was undertaken by one author (CP).  
Conference abstracts were included if these were indexed for MEDLINE and included essential study 
data such as group sizes and results data. Data was then extracted following a standardised format, 
capturing group sizes and diagnosis, baseline group age and cognitive functioning, the nature of the 
measure of symptom awareness, and study findings. The medication status during assessment was 
dichotomised to being ON medication, referring to participants being within the therapeutic window 
of their dopaminergic medication, or OFF medication, referring to participants being outwith the 
therapeutic phase of their medication. 
Variable terminology is in use in the literature. Terms commonly used are symptom 'awareness', or 
'insight' into symptoms, alongside 'anosognosia' and 'metacognition' or 'meta-memory'.  Whilst 
different authors use different precise definitions, broadly they refer to whether or not an individual 
is consciously aware of and able to accurately report a particular symptom (such as dyskinesias) or 
ability (such as memory function). This review will use the term 'awareness' to refer to whether 
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Box 1. Search strategy  
'Parkinson's' + 'Insight'                'Lewy body' + 'Insight' 
'Parkinson's' + 'Anosognosia'               'Lewy body' + 'Anosognosia' 
'Parkinson's' + 'Metacognition'               'Lewy body' + 'Metacognition'  
956 










26 further publications identified from references in screened literature 
 
 
                              Cognitive symptoms*             Motor symptoms*            Neuropsychiatric symptoms 
                                 21 publications                        16 publications                      10 publications 
 
* 1 publication32 reported both cognitive and motor findings therefore appears in both the 
‘cognitive’ and ‘motor’ groups.   
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3. Results 
3.1 Literature search 
A total of 956 publications were identified from the initial search (Box 1). After screening of titles 
and abstracts, 20 relevant publications were retained. Hand screening of the reference lists from 
these publications identified a further 26 relevant publications. These were then sub-divided 
according to whether they reported the investigation of insight into motor symptoms (16 
publications, Table 1), or neuropsychiatric and cognitive symptoms (reported elsewhere). 1 
publication32 reported both motor and cognitive findings. Study methodologies and key findings of 
each study are shown in Table 2, and an assessment of study quality in Table 3.  
3.2 Participant groups 
Participant group details are given in Table 1. All 16 studies recruited people with PD from specialist 
hospital clinics; no studies of motor symptom awareness in DLB were identified. The mean age of 
participants was typically in the 7th decade, and disease duration was between 4.00 and 13.50 years 
(disease duration was not stated in 4 studies). The majority of studies actively excluded people with 
cognitive impairment, typically using a cut off on the Mini-Mental State Examination (MMSE), with 
the minimum accepted MMSE for study inclusion ranging from of 23.00 to 28.00. Three studies did 
not report participants’ MMSE or Montreal Cognitive Assessment (MoCA) score. Overall the MMSE 
of study participants with PD (where reported) ranged from 23.40 to 29.23; the majority of studies 
reported a mean of 27.00 or greater. The number of participants with PD in individual studies ranged 
from 17 to 104, with a median of 25 PD participants per study (Table 1). Most study groups were 
small to medium, with only 6 studies containing more than 40 participants with PD. An excess of 
male participants was seen, with a female:male ratio of 1:1.21.     
3.3 Techniques for assessing symptom awareness 
All studies used discrepancy scores to rate awareness of motor functioning (Table 2). This technique 
involves asking the participant to rate their own ability, symptom or performance, and this score is 
compared to that given by a knowledgeable carer or expert rater. Most studies used a structured 
questionnaire or semi-structured interview, whilst others asked participants to perform a defined 
motor task and then record the severity of any motor symptoms they experienced during the task33. 
10 studies used a physician or study examiner to provide an ‘objective’ assessment of motor 
symptoms, whilst 8 used the opinion of a carer or other personal informant (note 1 study used both 
an examiner and an informant). One study used a modified mirror box task to capture changes to 
emotions during movement33. A modified version of the Wisconsin Card Sorting Test (WCST) was 
used in 1 study to examine metacognitive basis of altered awareness of dyskinesias.  
3.4 Timing of assessments 
Of the 16 studies identified, 5 assessed participants whilst ON and OFF dopaminergic medication34–38 
whilst 5 only tested during the ON state, and the remaining 6 studies did not report the medication 
status of study participants2,39–41 (Table 3). The majority of studies focused on unwanted positive 
symptoms (such as tremor and dyskinesias), rather than hypokinetic symptoms.  
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3.5 Key Findings 
Study findings are summarised in Table 2.  
Dyskinesia: 
The frequency of unawareness of dyskinesia severity ranged from 19.00%40 to 66.00%42of cognitively 
intact people with PD. Only one study found participants to over-estimate their dyskinesias41. In all 
other studies participants under-estimated the presence and/or severity of involuntary movements. 
Under-reporting of dyskinesias correlated with increasing symptom severity11,37,38, older age42, 
executive dysfunction34,36 and, in one study, left sided predominance of PD symptoms39.  
Bradykinesia: 
Two studies by Amanzio et al. did not identify evidence of altered awareness of hypo-bradykinesia 
when OFF dopaminergic medication, whilst two groups reported by Maier et al. did have reduced 
awareness for negative motor symptoms, in 54.80%38 and 53.90%42 of subjects. Under-reported 
bradykinesia OFF dopaminergic medication was typically mild, and correlated with reduced 
perfusion in right inferior frontal gyrus on FDG-PET38.  
General Physical Ability: 
When considering general physical ability and ADLs, no evidence of loss of awareness was shown 
overall2,43,44. A discrepancy between patient and informant reports of ADL functioning was seen in 
the study reported by Leritz et al, but controlling for MMSE rendered this effect non-significant2. 
Fleming et al. found no discrepancy between informant and patient ratings of physical functioning 
and quality of life43.
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4. Discussion 
Altered awareness of motor symptoms in PD is common and has been the subject of a wide range of 
investigations, often with conflicting findings. The incidence of partial or complete unawareness 
varies from two thirds of individuals42 to less than a quarter39.  Some studies have found under-
reporting of symptoms to be commoner in people with milder involuntary movements11,42, whilst 
others have demonstrated an association between increasing severity of motor symptoms and the 
incidence of unawareness37,38. These opposing results could indicate that there is bimodal 
distribution of unawareness, with very mild symptoms going unnoticed early on due to their 
insidious onset and lack of impact on overall motor functioning, whereas later in the disease course 
impairments in the neural processes controlling awareness cause under-reporting of more severe 
symptoms.  
An important consideration is the severity of symptoms which go unnoticed. This is inherently 
difficult to quantify, particularly as different studies use different (sometimes bespoke) rating scales 
for symptom severity and degree of unawareness. Maier et al. 201542 based symptom severity 
classification on expert physician opinion using the UPDRS-III scales45. They found 58.85% of 
cognitively intact PD participants to be unaware of mild symptoms, 34.46% unaware of moderate 
symptoms and 4.17% unaware of severe symptoms. Maier et al. 201237 found that the majority of 
participants showed a degree of symptom unawareness, with the unnoticed symptoms most 
commonly being mild (46.43% of unnoticed symptoms) or moderate (35.71% of unnoticed 
symptoms), and only 16.07% being severe. A very small proportion of the unnoticed symptoms were 
very severe (1.79% of all unnoticed symptoms). Amanzio et al. 201034 asked physicians to rate 
unawareness of symptoms, rating this from 0 (good awareness) to 4 (total loss of awareness). Mean 
physicians scores were 1.36 for dyskinesia unawareness and 0.24 for hypo-bradykinesia 
unawareness, indicating that unawareness was typically mild, but clearly worse for dyskinesias than 
hypo-bradykinesias. Maier et al. 201638 asked participants and physicians to rate the severity of 
motor symptoms during 15 tasks, with symptoms being rated out of 4 as per the UPDRS-III (where 0 
is no symptoms and 4 is symptoms which prevent the task being performed). The total possible 
discrepancy score was 60. Overall participants had a discrepancy score of 2.26 OFF medication 
(range 0-8, SD 2.34), and 3.06 ON (range 0-10, SD 3.10). Therefore, the absolute difference in 
symptom scoring between people with PD and physicians was relatively small. These findings 
indicate that unawareness of mild to moderate motor symptoms is common, but only a very small 
minority are unaware of severe symptoms. 
Motor symptoms can be divided into the positive, dyskinetic movements experienced in the ON 
state, when dopamine levels are highest, and the negative, hypokinetic issues experienced OFF 
medication, where dopamine levels are low. Amanzio et al. 201034 found awareness of bradykinesia 
in the OFF state to be greater than dyskinesia awareness ON, implying a negative effect of dopamine 
on awareness. Loss of awareness for dyskinesias was associated with lower scores on the Wisconsin 
Card Sorting Test, suggesting involvement of the prefrontal cortex. However, it should be noted that 
subjects reported greater anxiety and depressive symptoms OFF medication, which could have an 
impact on symptom perception. The same research group35 subsequently demonstrated a link 
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between dyskinesia awareness and metacognitive global monitoring, monitoring resolution 
(processes involved in internally assessing the likelihood of a response being correct) and control 
sensitivity (the degree of correlation between subjective confidence that a response is correct, and a 
decision to give that response). This implies that people with PD and reduced awareness may be 
impaired at monitoring their own performance and using feedback appropriately.  
These results are consistent with work using a mirror box task to manipulate participants' perception 
of their own movements33. A hand is placed inside the mirror box, and the participant instructed to 
move it in a particular direction. Placement of a mirror creates the illusion of movement in the 
opposite direction, so the direction of the perceived movement is incongruent to that expected. In 
healthy controls this causes a subjective feeling of strangeness, which is attributed to the mismatch 
between the planned movement and the visual feedback received. People with PD and reduced 
awareness of their dyskinesias showed altered experiences during the mirror box task, reporting 
both congruent and incongruent movements to feel equally strange. This implies that neural 
mechanisms monitoring planned vs actual movement are malfunctioning, with subsequent 
difficulties discriminating between accurate and inaccurate execution of planned movements.  
Theory of mind (ToM) has also been linked to symptom awareness, further implicating the 
prefrontal cortex46. ToM refers to the ability to understand and describe other people's mental 
states. It can be divided into cognitive ToM - the understanding of beliefs and intentions; and 
affective ToM - understanding emotions and feelings. The prefrontal cortex is implicated in both 
forms of ToM, with cognitive ToM linked to the dorsomedial prefrontal cortex, and affective ToM 
linked to the ventromedial prefrontal cortex47. Palermo et al.36 observed affective ToM performance 
to be linked to awareness of motor symptoms, unlike cognitive ToM. Therefore, the ventromedial 
prefrontal cortex may play a role in awareness of motor symptoms. The same study identified a link 
between performance on the Trails task and a dyskinesia self-monitoring task, further implicating 
executive functioning and the prefrontal cortex.  
The neural correlates of altered awareness of unwanted motor symptoms were investigated using 
FDG-PET by Maier et al.38 When OFF dopaminergic medication, loss of awareness for hypokinesia 
correlated with decreased perfusion in the right inferior frontal gyrus. In the ON state, altered 
awareness of positive or negative motor symptoms was linked to greater perfusion of the left 
inferior frontal gyrus, bilateral medial frontal gyrus, right superior frontal gyrus and right precentral 
gyrus. When specifically considering dyskinesias in the ON state, unawareness was linked to greater 
metabolism in the bilateral postcentral mid-cingulate cortex and left paracental lobule. These 
findings lend weight to the hypothesis that different neural circuits underpin awareness of 
hypokinesia and dyskinesia, and that dopamine replacement directly impacts on motor self-
awareness.  
PD and DLB are often defined as a purely dopaminergic disorder, but performance of a number of 
other neurotransmitters are also altered, and may play a role in altered symptom awareness.  
Acetylcholine is heavily implicated in the process of constructing conscious experience, in particular 
the basal forebrain and rostral brainstem cholinergic pathways31. Antagonistic agents can induce 
hallucinations and altered consciousness, whilst in AD and DLB the use of cholinesterase inhibitors 
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may alleviate psychotic symptoms. Cholinergic activity is significantly reduced in PD, with profound 
deficits found in PDD and DLB, to a greater extent than those found in AD48,49. Clearly acetylcholine 
deficits are therefore not the sole reason for loss of symptom awareness, as awareness is typically 
more severely affected in AD than in PD50.  
 
In healthy adults, manipulation of dopamine has a mixed effect on awareness. L-dopa has been 
found to improve awareness of memory retrieval performance3, an effect which could be mediated 
by dopamine stimulating GABAergic activity in the medial PFC, ACC and right insula23. Clos et al. 
found potentiation of dopamine release using low dose haloperidol reduced meta-memory when 
detecting new items, but improved meta-memory for previously presented items4. In a perceptual 
task, blockage of the D2 and D3 receptors with amisulpiride had no impact on confidence30. These 
mixed results may reflect different neural mechanisms underpinning awareness of performance in 
different cognitive domains, or the varying impacts of different pharmaceutical agents on the 
neurotransmitter and receptor brain milieu. Three major dopaminergic systems are implicated in 
altered awareness in PD: the nigrostriatal circuit; the mesolimbic circuit; and the mesocortical 
circuit. PD is characterised by a progressive dopaminergic deficit in the nigrostriatal circuit, which is 
treated by dopaminergic medications. In doing so it is possible that dopaminergic overload occurs in 
the mesolimbic and mesocortical circuits, and this has been hypothesised to be a cause of loss of 
symptom awareness11.  
 
Noradrenergic neurons in the locus coeruleus are severely affected in PD, and this potentially 
contributes to motor and non-motor symptoms. The locus coeruleus receives glutaminergic 
afferents from the OFC and ACC, areas known to be involved in self-awareness. In healthy controls, 
the inhibition of central noradrenergic transmission can improve metacognition, via better 
recognition of inaccurate choices30. However the specific role of noradrenaline in symptom 
awareness in PD has not been investigated. The serotonergic system is also compromised in PD, and 
implicated in the development of hallucinations and other psychotic symptoms51, but the potential 
consequences for symptom awareness are unknown. 
 
It is possible that cognitive performance modulates awareness of motor symptoms, i.e. individuals 
with more severe cognitive impairments also showing greater difficulties with awareness32,33. Leritz 
et al.2 found differences in MMSE to explain discrepancies in self and carer ratings of ADL ability, and 
Maier et al. 201542 found increasing age to correlate with worsening symptom awareness. Seltzer et 
al.32 identified worsening cognition as a correlated to greater symptom unawareness. Contrary to 
this hypothesis, Palermo et al.36 found no association between global cognition and dyskinesia 
awareness. Most studies have focused on cognitively intact individuals, and there is a need for high 
quality research studies to elucidate the impact of cognitive functioning on motor symptom 
awareness. There is also a lack of studies of motor symptom awareness in DLB.  
Classical descriptions of loss of symptom awareness come from the stroke literature, and it is well 
recognised that individuals with damage to the right hemisphere are particularly affected. 
Extrapolating from this, it is logical to hypothesise that people with PD affecting the right 
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hemisphere in particular (and consequently displaying left sided motor symptoms at onset) might 
experience more severe loss of symptom awareness. Some studies support this hypothesis37–39, 
although others have found no association35. The issue is further clouded by a trend for right sided 
symptoms to cause greater functional impairments, most likely due to the predominance of right 
handed individuals2.  
There are a number of methodological limitations to the current literature in PD. Most studies have 
focussed on seemingly cognitively intact individuals, as defined by a tool such as the MMSE. The 
MMSE is a useful screening tool, but is insufficient to accurately distinguish normal cognition from 
MCI or early dementia in PD. The Movement Disorders Society has developed detailed testing 
recommendations for the diagnosis of MCI due to PD, and future studies would benefit from using 
these more robust criteria52,53. There is a paucity of studies specifically investigating the impact of 
cognitive decline on symptom awareness, and very few studies to date have assessed changes to 
awareness longitudinally. Given the chronic nature of PD and high incidence of progressive cognitive 
decline, longitudinal studies are needed to accurately establish the neural underpinnings of 
symptom awareness, the most effective assessment techniques and ultimately generate novel tools 
to support those affected. 
Many studies have relied on discrepancy scores as a measure of awareness. These are potentially 
open to significant bias if the informant is unduly influenced by a desire to protect the participant 
and therefore under-report symptoms, or is experiencing significant carer burden and consequently 
over-report symptoms. Furthermore, even a close relative may not be fully aware of an individual's 
exact mental state or experience of living with subtle cognitive change.  
Altered symptom awareness in neurodegenerative conditions can greatly exacerbate the impact of 
the primary condition itself. Those affected may not seek appropriate help and support or refuse 
essential care. Studies of people with Alzheimer's disease have reported worsening insight to be 
associated with greater carer burden and strain. As the world's population ages the prevalence of 
Parkinson's is predicted to increased significantly18. Understanding how symptom awareness 
changes during the life course of PD, and the impact this has on those affected and their significant 
others and caregivers is a vital step in the pathway towards developing effective management and 
therapeutic techniques.  
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Table 1. Studies of altered awareness of motor symptoms in PD and DLB. 





(MMSE unless otherwise stated†) 
Amanzio 2010 34 25 people with PD & motor 
fluctuations (13♀12♂) 
59.12 (range 39.00-74.00) 137.60 (range 84.00-
240.00) 
27.80. Excluded if MMSE <24.00 
Amanzio 2014 35 48 people with PD & motor 
fluctuations (22♀26♂) 
65.79 (6.52) 137.76 (78.24) 27.65. Excluded if MMSE <24.00 
Fleming 2005 43 64 people with PD (sex ratio 
not stated) 
74.41 (5.72) Not stated MMSE not stated. Those with dementia 
excluded 
Jenkinson 2009 33 6 people with PD & 
anosognosia (2♀4♂) 
11 with PD & intact awareness 
(6♀5♂) 
22 controls (12♀10♂) 
Anosognosia 69.67 (8.76) 
Intact awareness 65.20 
(7.63) 
Controls      66.86 (6.82) 
Not stated PD & anosognosia 26.67 (2.80) 
PD & intact awareness 29.23 (1.12) 
Controls 29.23 (0.81) 
Leritz 2004 2 32 people with Left sided PD 
(13♀19♂) 
16 people with Right sided PD 
(7♀9♂) 
Left 64.05 (7.14) 
Right 62.38 (7.36) 
Left mean 14.13 years 
(7.84) 
Right 13.00 (3.88) 
Left 28.00 (1.90)  
Right 29.06 (1.12) 
Excluded if MMSE<=24.00 
Maier 2015 42 104 PD patients (36♀68♂) Median 66.50 (range 41.00-
80.00) 
Median 72.00 (range 0-
240.00) 
Median MMSE 29.00 (range 27.00-30.00)   
Excluded if MMSE<27.00 
Maier 2012 37 28 people with PD (8♀20♂) 60.32 (9.68) Mean 7.68 years (9.68) 28.71 (1.41)  
Excluded if MMSE <=25 
Maier 2016 38 31 people with PD (8♀23♂) 65.13 (6.51) 104.04 (54.84) 28.74 (1.18) 
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Martinez-Martin 2003 44 60 people with PD (34♀26♂) 66.61 (7.97) Not stated MMSE not stated (5 subjects had mild to 
moderate cognitive impairment) 
Palermo 2017 36  41 PD & motor fluctuations 
(18♀23♂) 
65.00 (6.58) Median 132.00 (IQR 
108.00-168.00) 
28.32 (1.37) 
Pietracupa 2013 39 30 PD & levodopa induced 
dyskinesias (17♀13♂) 
15 controls (8♀7♂) 
PD group 67.40 (8.20) 
Controls 66.80 (9.90) 
138.00 (64.80) 28.10 (2.10)  
Excluded if MMSE <=26.00 
(MMSE for control group not stated) 
Pillai54  30 PD-MCI (8♀22♂) 
17 non-amnestic MCI (6♀11♂) 
33 amnestic MCI (16♀17♂) 
PD-MCI 67.80 (7.40) 
Non-amnestic MCI 69.80 
(5.90) 
Amnestic MCI 69.6 (6.10) 
Not stated Mean (SD) MoCA:  
PD-MCI  23.70 (0.30)  
Non-amnestic MCI   23.00 (2.90) 
Amnestic MCI           20.60 (2.70) 
Seltzer 200132 32 PD (12♀20♂) 
31 AD (17♀14♂) 
PD 72.20 (11.40) 
AD 76.60 (8.00) 
PD 64.80 (44.40) 
AD 32.40 (19.20)  
PD 23.40 (11.40) 
AD 18.50 (5.20) 
Sitek 2011a 40 21 with PD & dyskinesia 
(11♀10♂) 
63.29 (8.82) 146.28 (56.76) 27.53 (1.86). Excluded if MMSE <25 
Sitek 2011b 41 25 people with PD & 
dyskinesias  (13♀12♂) 
21 PD no dyskinesia (6♀15♂) 
23 with Huntington’s disease 
(9♀14♂)         
20 cervical dystonia (12♀8♂) 
PD & dyskinesia 65.68 
(10.03) 
PD no dyskinesia 64.67 
(7.59) 
HD 49.83 (11.12) 
Cervical dystonia 51.75 
(12.98) 
PD & dyskinesia 144.00 
(SD not given) 
PD no dyskinesia 48.00 
(SD not given) 
PD & dyskinesias 27.00 (mean, SD not given) 
PD no dykinesias 28.00 (mean, SD not given) 
HD 26.00 (median)              
Cervical dystonia 28.50 (mean, SD not given) 
Vitale 2001 11 ‡ 13 people with PD & 
dyskinesias 
9 people with HD (sex ratio not 
given) 
PD group median 60.10 
(range 49.00-77.00) 
HD group median 58.50 
(range 31.00-71.00 
PD group median 
138.00 
(range 72.00-240.00) 
All MMSE=>23; mean MMSE not stated.  
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† Age, disease duration and MMSE values are given as mean and standard deviation unless otherwise stated.  






Table 2. Awareness Assessment Methodology & Key Findings 
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AUTHORS MOTOR ASSESSMENT METHODS & KEY FINDINGS 
Amanzio 2010 34 GAM: physician observation of subject awareness of hypo-bradykinesia & dyskinesia (scale range 0: good awareness to 4: no awareness of 
motor symptoms).  Mean GAM of 1.36 for dyskinesias ON & 0.24 for hypo-bradykinesias OFF medication 
Discrepancy scores based on self-assessment & examiner assessment of hypo-bradykinesias & dyskinesias during simple motor tasks.  
Dyskinesias rated from 0 (none) to 3 (severe); on average subjects rated dyskinesias as 0.71 less severe than examiners did.  
Reduced dyskinesia awareness ON medication (which correlated with executive function). Preserved awareness of hypo-bradykinesia OFF  
Amanzio 2014 35 GAM; discrepancy scores for hypo-bradykinesia & dyskinesias (as per Amanzio 2010). Absolute values for these not reported.  
Reduced awareness of dyskinesias associated with metacognitive global monitoring, monitoring resolution & control sensitivity. No 
associations with disease duration, symptom laterality, age or L-dopa dose. Participants had intact awareness of hypo-bradykinesia. 
Fleming 2005 43 Questionnaires (CES-D & PDQ-39) completed by subjects & informants & discrepancies between scores calculated. 
There was no significant differences in ratings of disability, QoL and physical activity. 
Jenkinson 2009 33 Subjects rated how ‘strange’ movements felt during a mirror box task (range 0 ‘no sense of strangeness to 9 ‘very strange’). Anosognosic 
group rated congruent movements as feeling strange (mean 3.83) unlike those with intact awareness (0.68) & controls (0.27). No difference in 
ratings on incongruent movements (anosognosic group 4.24, intact awareness group 2.86, controls 3.64).  Anosognosic PD group unable to 
distinguish congruent & incongruent movements, suggesting failure to differentiate between intended and actual movements. 
Leritz 2004 2 Patients & carers completed motor & ADL parts of UPDRS, plus Schwab & England ADL scale (where 100%: complete independence, 1%: total 
dependency). Patients self-rated as less impaired on ADLs compared to carers (Schwab & England 53.50% vs 46.33 in left sided group, 60.00 
vs 53.33 in left sided group) but controlling for MMSE rendered this non-significant. Symptom laterality did not affect awareness. 
Maier 2015 42 Discrepancy scores calculated from subject & expert ratings of positive & negative motor symptoms during filmed motor tasks.  
66.35% had impaired awareness of motor symptoms. 58.85% were unaware of mild symptoms, 36.46% unaware of moderate symptoms, 
4.17% unaware of severe symptoms & 0.52% unaware of very severe symptoms. Older age correlated with greater unawareness. 7.80% of 
subjects reported a symptom not noticed by expert raters.  
Maier 2012 37 Discrepancy scores calculated from subject & expert ratings of positive & negative motor symptoms during filmed motor tasks (UPDRS-III 
scales). 60.71% had impaired awareness. Regarding unnoticed symptoms, 46.43% were mild, 35.71% moderate, 16.07% severe & 1.79% very 
severe. Motor symptoms & specifically left sided symptom severity OFF were associated with unawareness. Gait instability correlated with 
unawareness.   
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Maier 2016 38 Discrepancy scores calculated from subject & expert ratings of positive & negative motor symptoms during filmed motor tasks (as per Maier 
201542).  Total severity scores for motor symptom unawareness calculated based on 15 possible symptoms, each rated from 0 (symptom 
absent) to 4 (unable to perform action but unaware of this). Total possible score 60. Mean total unawareness scores of 2.26 ON & 3.06 OFF.  
OFF medication: hypokinesia unawareness linked to reduced perfusion in right inferior frontal gyrus and left sided PD onset. ON medication: 
overall unawareness of hypokinesia and dyskinesia correlated with greater metabolism in prefrontal regions and right precentral gyrus 
Martinez-Martin 
2003 44 
Patients, carers & physicians rated symptoms on a modified UPDRS-ADL. Ratings of physical disability by patients were marginally higher, but 
the only significant difference between raters was on the ‘falling’ item (where patients & carers rated this as worse than physicians). 
Depression weakly influenced self-rating of disability & ADL scores. Carer burden did not influence inter-rater group agreement.  
Palermo 2017 36  Dyskinesia awareness rated by physician using the GAM, & the Dyskinesias-Subtracted Index (the difference between subject & physician 
rating of dyskinesias during set motor tasks, with possible scores from 0: dyskinesia absent to 3: severe dyskinesia).  
Mean GAM score 1.51 (SD 1.00), mean Dyskinesias-Subtracted Index 1.27 (SD 0.81) 
Dyskinesia unawareness was associated with the Reading Mind in the Eyes & Trail making tasks performance, but not with global measures of 
cognition. 
Pietracupa 2013 39 Patients self-rated their dyskinesias in 7 body areas during actions & on watching film of these, rating severity from 0 to 4. Discrepancy scores 
calculated comparing patient ratings with physician ratings. Patients’ mean rating 5.50 (SD 4.30) vs physicians 7.60 (SD 4.20) 
23.3% were completely unaware of dyskinesias during actions but 93.70% recognised dyskinesias on watching a film of themselves. 
Awareness was worse for truncal dyskinesia compared to limb. Unawareness greater in those with left sided symptoms predominance. 
Pillai54  Discrepancy scores between patient and informant on the Anosognosia-Questionnaire Dementia (30 ADL questions scored from 0 to 3). PD-
MCI subjects self-rated as being more impaired than informants (mean discrepancy -4.60, SD 12.30). Amnestic & non-amnestic MCI groups 
self-rated as being less impaired (mean discrepancy scores of 1.40 & 1.60). 11.40% of those with PD-MCI showed anosognosia for ADL ability 
(defined as a discrepancy score of >=14); rates in the other groups were similar. In PD-MCI depressive symptoms were associated with lower 
self-appraisal scores. 
Seltzer32 Discrepancy scores (patients vs carers) using Patient Competency Rating Scale, Motor-Unified Rating Scale for Parkinsonism & Clinical 
Dementia Rating Scale. Clinician ratings on the M-URSP. Patients rated themselves as less impaired on the M-URSP compared to carers. Carer 
motor scoring correlated with clinician ratings, suggesting this is a valid measure. Reduced awareness correlated with impaired cognition 
(particularly memory) in the PD group.   
Sitek 2011a 40 Patients & study partners rated motor symptoms on pre-recorded films, and rated symptoms experienced by the patient (max scores 15 for 
parkinsonian symptoms, 15 for dyskinesias). No overall significant differences between patient & partner ratings.  Raw data showed 9% of 
patients to be unaware of all dyskinesias, and 19% significantly under-estimated dyskinesias (defined as more than 4 point discrepancy). 
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Abbreviations: ADL Activities of Daily Living; AIMS Abnormal Involuntary Movement Scale; CES-D Centre for Epidemiological Study-Depression; GAM Global 
Awareness of Movement; PDQ-39 Parkinson’s Disease Questionnaire; UPDRS Unified Parkinson’s Disease Rating Scale  
Sitek 2011b 41 Patients & informants completed the Motor Impairment Scale (rating patient motor symptoms in comparison to reference films) & the Self-
Assessment Parkinson’s Disease Disability Scale for ADLs. People with PD and dyskinesias over-rated choreic movements.  
Vitale 2001 11 ‡ Patients evaluated their dyskinesias during specified motor tasks. Physicians rated dyskinesias on the Abnormal Involuntary Movement Scale 
& the Goetz Dyskinesia Rating Scale. Physicians rated unawareness from 0 (fully aware) to 8 (totally unaware). Significant negative 
relationship found between total score on AIMS & unawareness of movements on standing, & between upper limb AIMS score & 
unawareness at hand pronation. Unawareness did not correlate with total UPDRS, Goetz score or disease duration.  
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Table 3. Study quality summary.  
AUTHORS STUDY CHARACTERISTICS 
Amanzio et al. 34 Cross-sectional study. Well characterised group. Assessed ON and OFF medication.  
Amanzio et al. 35 Cross-sectional study, good group size. Well characterised group. Group assessed ON and OFF medication.  
Fleming et al. 43 Cross sectional study, good group size but limited neuropsychological characterisation. Medication status of PD participants during assessment not given.  
Jenkinson et al. 33 Case-control study. Small group sizes but well characterised. Medication status of participants during assessment not given.  
Leritz et al. 2 Cross-sectional study. Good group size, well characterised. All participants tested ON medication.  
Maier et al. 42 Cross-sectional study. Good group size, well characterised. All participants tested ON medication. 
Maier 37 Cross-sectional study. Moderate group size; well characterised. Participants assessed ON and OFF medication.  
Maier 38 Cross-sectional study. Moderate group size. Assessed ON and OFF medication.   
Martínez-Martín44 Case-control study. Good group sizes; limited cognitive characterisation. Medication status during assessment not stated.  
Palermo36  Cross-sectional study. Moderate group size; well characterised. Participants assessed ON and OFF medication.  
Pietracupa 39 Cross-sectional study. Moderate group size; well characterised. All participants assessed ON medication.  
Pillai54 Cross-sectional study. Moderate group sizes; well characterised. Medication status during assessment not stated.  
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Seltzer32 Cross-sectional study. Moderate groups sizes; well characterised. Medication status during assessment not stated.  
Sitek 40 Cross-sectional study. Small group sizes; well characterised. Assessed ON medication.  
Sitek 41 Case-control study. Small group sizes; well characterised. PD participants assessed ON medication.  
Vitale 11 Case-control study. Small group sizes; limited group characteristics reported.  Excluded if MMSE <23. Medication status of PD participants during assessment not given.  
 
This article is protected by copyright. All rights reserved.
